Patents Examined by Garnette Draper
-
Patent number: 5945097Abstract: A method for lowering the blood cholesterol levels in mammals and humans by administering IL-10 is disclosed. Preferred dosages and methods of administration are also disclosed.Type: GrantFiled: September 5, 1997Date of Patent: August 31, 1999Assignee: Schering CorporationInventor: David Cutler
-
Patent number: 5204097Abstract: The invention relates to a number of synthetic polypeptides which correspond to a part of the sequences of the Shiga B peptide chain. More specifically, the invention relates to polypeptides corresponding to the residues 5 to 18, 7 to 26, 13 to 26, and 19 to 29 of said B chain. The invention further relates to the conjugates of each of these with a suitable carrier and to polymers of each or these obtained by polymerization with a suitable polymerization agent: these can be used as effective vaccines which afford protection against Shiga toxin. Anti-peptide anti-sera are effective in neutralizing to a large extent the biological activity of Shiga toxin.Type: GrantFiled: June 9, 1989Date of Patent: April 20, 1993Assignee: Yeda Research and Development Company LimitedInventors: Ruth Arnon, Ilana Harari, Gerald T. Keusch, Arthur Donohue-Rolfe
-
Patent number: 4997916Abstract: A method is provided for recovering a purified animal growth hormone or a polypeptide analog thereof having substantially the same amino acid sequence as, and the biological activity of, the corresponding naturally-occurring animal growth hormone from a bacterial cell in which the animal growth hormone or polypeptide analog has been produced by means of expression of a plasmid encoding the hormone or polypeptide analog which comprises: (a) disrupting the cell wall of the bacterial cell in a buffered neutral pH solution so as to produce a lysate containing precipitated hormone or polypeptide analog; (b) recovering the resulting precipitated hormone or polypeptide analog; (c) suspending the precipitated hormone or polypeptide analog so recovered in distilled water; (d) treating the resulting precipitate-containing suspension with a sodium hydroxide solution having an alkaline pH of about 11.Type: GrantFiled: March 7, 1989Date of Patent: March 5, 1991Assignee: Bio-Technology General Corp.Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
-
Patent number: 4996296Abstract: Substantially pure cromolyn binding protein is prepared by means of affinity chromatography of cromolyn derivatives bound to insoluble matrices. Aminocromolyn is prepared by a six-step synthesis and amine derivatives thereof are prepared by conventional means. Obtaining a compound having an amine group instead of the OH group at the 2-carbon of the propane link of cromolyn permits many kinds of reactions without interfering with the portion of the cromolyn molecule with causes its pharmacological activity. The cromolyn derivatives can be conjugated to proteins such as BSA by means of glutaraldehyde cross-linking and such conjugates can be covalently bound to agarose beads. Cromolyn binding protein can be isolated by passing lysates of RBL-2H3 cells through chromatographic columns packed with such beads. The cromolyn binding protein can be further purified by means of lectin-agarose columns.Type: GrantFiled: July 27, 1987Date of Patent: February 26, 1991Assignee: Yeda Research & Development Co., Ltd.Inventors: Israel Pecht, Stefan Hemmerich
-
Patent number: 4992271Abstract: An improved process for recovering and purifying lipophilic recombinant proteins such as human .beta.-interferon and interleukin-2 from their hosts yields a protein preparation which may be formulated into a stable pharmaceutical composition having a therapeutically effective amount of the biologically active recombinant lipophilic protein dissolved in a non-toxic, inert, therapeutically compatible aqueous-based carrier medium at a pH of 6.8 to 7.8 which medium also contains a stabilizer for the protein, such as human serum albumin, normal serum albumin and human plasma protein fraction.Type: GrantFiled: September 13, 1985Date of Patent: February 12, 1991Assignee: Cetus CorporationInventors: Wolfgang H. Hanisch, Peter M. Fernandes, Terrance Taforo
-
Patent number: 4977248Abstract: A method for the renaturation of unfolded proteins comprises reversibly immobilizing the denatured protein on a solid phase and inducing folding of the immobilized protein by progressively reducing with time the concentration of a denaturing agent in the solvent in contact with the solid phase. The refolded protein is recovered from the solid phase in native form. The proteins can be folded and recovered in high yield in a small volume of buffer.Type: GrantFiled: August 10, 1989Date of Patent: December 11, 1990Inventor: Thomas E. Creighton
-
Patent number: 4963354Abstract: Tumor necrosis factors, alone or together with cytokines such as IL-1 or INF-.gamma., are capable of serving as non-toxic vaccine adjuvants.Type: GrantFiled: January 21, 1987Date of Patent: October 16, 1990Assignee: Genentech, Inc.Inventors: H. Michael Shepard, James E. Talmadge
-
Patent number: 4962188Abstract: Conjugates comprising recombinant ricin toxin A chain and a binding moiety which may be an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab').sub.2 fragments of monoclonal or polyclonal antibodies, hormones, lectins or other compounds that are recognized by cell receptors, are described and claimed.Type: GrantFiled: September 30, 1986Date of Patent: October 9, 1990Assignee: Cetus CorporationInventor: Arthur E. Frankel
-
Patent number: 4962207Abstract: The present application discloses novel potassium salts of particular tellurium and selenium compounds which are useful for the stimulation of the production of cytokines.Type: GrantFiled: October 9, 1987Date of Patent: October 9, 1990Assignee: Bar-Ilan UniversityInventors: Michael Albeck, Benjamin Sredni
-
Patent number: 4962189Abstract: The invention herein is directed to methods using Procion dyes to perform separations of interest in manipulating the NAD.sup.+ -independent ribotoxins. The methods are useful for preparing therapeutic agents containing these ribotoxins or their A polypeptide components. This separation method has been applied in particular to preparing hybrid toxins containing ricin toxins, both for purifying the resulting products and also for separating the components intended to be used in the preparation of these end products. In addition, a novel ricin isotoxin prepared using the method of the invention is disclosed.Type: GrantFiled: December 11, 1987Date of Patent: October 9, 1990Assignee: Cetus CorportionInventor: Will Bloch
-
Patent number: 4961926Abstract: This invention provides method of preventing mucositis in a subject susceptible to mucositis comprising administering to the subject a prophylactically effective amount of granulocyte colony stimulating factor or a polypeptide analog thereof having substantially the same amino acid sequence and the activity of naturally occurring granulocyte colony stimulating factor. This invention further provides a method of treating mucositis in a subject having mucositis comprising administering to the subject a therapeutically effective amount of granulocyte colony stimulating factor or a polypeptide analog thereof having substantially the same amino acid sequence and the activity of naturally occurring granulocyte colony stimulating factor.Type: GrantFiled: November 19, 1987Date of Patent: October 9, 1990Assignee: Sloan-Kettering Institute For Cancer ResearchInventor: Janice L. Gabrilove
-
Patent number: 4959455Abstract: A novel family of primate IL-3 polypeptides is provided via recombinant techniques.Type: GrantFiled: March 4, 1987Date of Patent: September 25, 1990Assignee: Genetics Institute, Inc.Inventors: Steven C. Clark, Agnes B. Ciarletta, Yu-Chung Yang
-
Patent number: 4958009Abstract: Immunotoxins comprising a cytotoxic moiety and monoclonal antibodies which bind to human ovarian cancer tissue having at least one of the following capabilities are claimed: cytotoxic ID.sub.50 of 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens to which the monoclonal antibody of the immunotoxin bind are identified and characterize the immunotoxins. Methods of killing human ovarian cancer cells, retarding the growth of human ovarian cancer tumors in mammals or extending the survival of mammals carrying human ovarian cancer tumors are claimed.Type: GrantFiled: July 6, 1987Date of Patent: September 18, 1990Assignee: Cetus CorporationInventors: Michael J. Bjorn, David J. FitzGerald, Arthur E. Frankel, Walter J. Laird, Ira H. Pastan, David B. Ring, Mark C. Willingham, Jeffrey L. Windelhake
-
Patent number: 4958007Abstract: A method is provided for extracting human interleukin-4 (IL-4) from IL-4 expressing bacterial cells. The method comprises treating the bacterial cells with a deactivating agent, disrupting the cell membrane and recovering the IL-4.Type: GrantFiled: May 17, 1988Date of Patent: September 18, 1990Assignee: Schering-Plough Corp.Inventors: Yair Alroy, Paul Leibowitz
-
Patent number: 4957739Abstract: Novel compositions are disclosed for use in the treatment or diagnosis of bovine pasteurellosis, commonly referred to as Shipping Fever. Cell-free Pasteurella haemolytica supernatants are employed to provide individual antigen compositions, identified through reaction with sera from naturally-infected or convalescent cattle. In particular, at least seven individual P. hameolytica antigen groups were recognized in cell-free culture supernatants. Purified P. haemolytica supernatant, formulated in a suitable pharmaceutical vaccine composition is shown to elicit a specific immune response, in both cows and rabbits, directed against the individual immunoreactive P. haemolytica polypeptides identified. Also disclosed are novel recombinant cells, plasmids and bacteriophage which include transcriptionally active P. haemolytica antigen genes. Recombinant clones are similarly selected to be reactive with naturally-infected antisera.Type: GrantFiled: August 13, 1987Date of Patent: September 18, 1990Assignee: Board of Regents, The University of Texas SystemInventors: Peter Berget, Michael Engler, Sarah Highlander, George Weinstock
-
Patent number: 4957903Abstract: The invention relates to a fully solubilizable fibrin based composition, which is characterized by the combination that the fibrin is desAA-fibrin or desAA-fibrin from which the C-terminal portions of the .alpha.-chains have been removed by enzymatic digestion, and that the solubilizing agent is a tetrapeptide containing the amino acid sequence -L-prolyl-L-arginyl-, preferably glycyl-L-prolyl-L-arginyl-L-prolin.The full solubility of the fibrin makes possible new uses within the area of determination of important fibrinolytical parameters, and the invention also relates to three such important alternative uses. A first use according to the invention is the use of the composition in connection with detection or quantification of the activity of the enzyme tissue plasminogen activator.Type: GrantFiled: November 20, 1986Date of Patent: September 18, 1990Assignee: Biopool International, Inc.Inventor: Mats G. Ranby
-
Patent number: 4956453Abstract: Immunotoxins comprising a cytotoxic moiety and an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab').sub.2 fragments of a monoclonal antibody, which binds to human ovarian cancer tissue, having one of the following capabilities are claimed: cytotoxic ID.sub.50 of about 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals, or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens or epitopes to which the monoclonal antibodies bind are identified and characterize the immunotoxins. In a preferred embodiment an immunotoxin comprising at least an antigen binding portion of a monoclonal antibody, which binds to human transferrin receptor, but does not block binding of transferrin to the receptor, is described and claimed. Immunotoxin comprising the F(ab').sub.2 region of the antitransferrin monoclonal antibody are also claimed.Type: GrantFiled: July 6, 1987Date of Patent: September 11, 1990Assignee: Cetus CorporationInventors: Michael J. Bjorn, Arthur E. Frankel, Walter J. Laird, David B. Ring, Jeffrey L. Winkelhake
-
Patent number: 4956278Abstract: Anaplasma marginale antigen, antigen compositions, vaccine and process for the production of said antigen, antigen composition and vaccine are disclosed. The Anaplasma marginale is free of the erythrocyte antigens that cause neonatal isoerythrolysis, and effective as a vaccinate which will not only protect the vaccinate against bovine anaplasmosis, but does not induce neonatal isoerythrolysis in offspring of vaccinates.Type: GrantFiled: February 23, 1988Date of Patent: September 11, 1990Assignee: Louisiana State UniversityInventors: Lewis T. Hart, Donald G. Luther, William J. Todd
-
Patent number: 4956454Abstract: Platinum co-ordination compounds comprising at least one amine ligand and a functional group remotely bonded to the amine ligand, which functional group may be linkable to a monoclonal antibody to provide a moiety which stabilizes the antibody against in vivo hydrolysis.Type: GrantFiled: April 21, 1988Date of Patent: September 11, 1990Assignee: Johnson Matthey PLCInventors: James G. Heffernan, Paul C. Hydes, Donald H. Picker
-
Patent number: 4952403Abstract: Healing of injured avascular tissue is promoted by applying angiogenic factor in proximity to the injured tissue.Type: GrantFiled: June 8, 1988Date of Patent: August 28, 1990Assignee: President and Fellows of Harvard CollegeInventors: Bert L. Vallee, Thomas V. King